1.2734
Schlusskurs vom Vortag:
$1.07
Offen:
$1.07
24-Stunden-Volumen:
2.36M
Relative Volume:
0.99
Marktkapitalisierung:
$142.71M
Einnahmen:
$13.45M
Nettoeinkommen (Verlust:
$-178.23M
KGV:
-0.7718
EPS:
-1.65
Netto-Cashflow:
$-132.53M
1W Leistung:
+16.36%
1M Leistung:
+12.16%
6M Leistung:
-42.89%
1J Leistung:
-68.08%
Fate Therapeutics Inc Stock (FATE) Company Profile
Firmenname
Fate Therapeutics Inc
Sektor
Branche
Telefon
858.875.1803
Adresse
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Vergleichen Sie FATE mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
FATE
Fate Therapeutics Inc
|
1.245 | 122.66M | 13.45M | -178.23M | -132.53M | -1.65 |
![]()
ONC
Beigene Ltd Adr
|
232.89 | 25.21B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
438.28 | 112.83B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.2409 | 40.72M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
594.37 | 62.15B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
71.35 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-11-18 | Hochstufung | BofA Securities | Underperform → Neutral |
2024-06-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
2023-03-27 | Fortgesetzt | Wells Fargo | Equal Weight |
2023-01-24 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2023-01-06 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
2023-01-06 | Herabstufung | BofA Securities | Buy → Underperform |
2023-01-06 | Herabstufung | Cowen | Outperform → Market Perform |
2023-01-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
2023-01-06 | Herabstufung | Stifel | Buy → Hold |
2023-01-06 | Herabstufung | Truist | Buy → Hold |
2023-01-06 | Herabstufung | Wedbush | Outperform → Neutral |
2023-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
2022-12-22 | Herabstufung | Oppenheimer | Outperform → Perform |
2022-12-15 | Eingeleitet | Goldman | Sell |
2022-11-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
2022-10-10 | Eingeleitet | Canaccord Genuity | Buy |
2022-08-18 | Fortgesetzt | Wells Fargo | Overweight |
2022-07-28 | Eingeleitet | Needham | Hold |
2022-07-11 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
2022-06-03 | Eingeleitet | Robert W. Baird | Neutral |
2022-02-11 | Fortgesetzt | BMO Capital Markets | Market Perform |
2021-12-15 | Hochstufung | Wedbush | Neutral → Outperform |
2021-12-07 | Eingeleitet | Cowen | Outperform |
2021-11-09 | Hochstufung | Citigroup | Neutral → Buy |
2021-08-26 | Eingeleitet | Morgan Stanley | Equal-Weight |
2021-06-07 | Hochstufung | H.C. Wainwright | Neutral → Buy |
2021-05-07 | Hochstufung | Wedbush | Neutral → Outperform |
2021-04-26 | Fortgesetzt | Jefferies | Buy |
2021-02-26 | Eingeleitet | BofA Securities | Buy |
2021-02-26 | Herabstufung | Wedbush | Outperform → Neutral |
2021-02-11 | Herabstufung | Citigroup | Buy → Neutral |
2021-01-27 | Fortgesetzt | H.C. Wainwright | Neutral |
2020-05-13 | Eingeleitet | H.C. Wainwright | Buy |
2020-03-04 | Eingeleitet | Barclays | Overweight |
2020-01-09 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
2019-12-30 | Bestätigt | Mizuho | Buy |
2019-12-09 | Hochstufung | Wells Fargo | Market Perform → Outperform |
2019-11-12 | Eingeleitet | SunTrust | Buy |
2019-11-06 | Herabstufung | Wells Fargo | Outperform → Market Perform |
2019-10-01 | Eingeleitet | Stifel | Buy |
2019-08-09 | Eingeleitet | BTIG Research | Buy |
2019-07-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
2019-07-12 | Eingeleitet | Oppenheimer | Outperform |
2019-06-13 | Eingeleitet | Mizuho | Buy |
2019-06-07 | Eingeleitet | ROTH Capital | Neutral |
2019-05-31 | Eingeleitet | Guggenheim | Buy |
2019-05-24 | Fortgesetzt | Citigroup | Buy |
2019-03-28 | Eingeleitet | SVB Leerink | Outperform |
2019-01-03 | Herabstufung | Stephens | Overweight → Equal-Weight |
2018-11-05 | Eingeleitet | Jefferies | Buy |
2018-08-01 | Eingeleitet | Citigroup | Buy |
2018-03-06 | Herabstufung | H.C. Wainwright | Buy → Neutral |
Alle ansehen
Fate Therapeutics Inc Aktie (FATE) Neueste Nachrichten
Price T Rowe Associates Inc. MD Cuts Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
StockNews.com Upgrades Fate Therapeutics (NASDAQ:FATE) to Hold - Defense World
Barclays Cuts Fate Therapeutics (NASDAQ:FATE) Price Target to $2.00 - Defense World
Wedbush Predicts Increased Earnings for Fate Therapeutics - Defense World
What is Leerink Partnrs’ Estimate for FATE Q2 Earnings? - Defense World
Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus - MSN
Needham & Company LLC Reiterates “Hold” Rating for Fate Therapeutics (NASDAQ:FATE) - Defense World
Fate Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Fate Therapeutics (FATE) Faces Significant Price Target Reductio - GuruFocus
FATE Stock Update: Analyst Lowers Price Target, Maintains Neutra - GuruFocus
4 Analysts Assess Fate Therapeutics: What You Need To Know - Benzinga
Barclays Adjusts Fate Therapeutics (FATE) Price Target Amid Q1 R - GuruFocus
Baird Revises Fate Therapeutics (FATE) Price Target Post-Q1 Resu - GuruFocus
FATE Therapeutics Exceeds Revenue Estimates with Strong CAR T-Ce - GuruFocus
Fate Therapeutics: Q1 Earnings Snapshot - CT Insider
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates - NewsBreak: Local News & Alerts
Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates - The Manila Times
FATE THERAPEUTICS INC SEC 10-Q Report - TradingView
What Is Going On With Fate Therapeutics Inc (NASDAQ: FATE)? - Stocksregister
Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Purchased by Dimensional Fund Advisors LP - Defense World
Hsbc Holdings PLC Has $179,000 Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Sold by MetLife Investment Management LLC - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Purchased by Wells Fargo & Company MN - Defense World
Fate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy Sector - Seeking Alpha
Fate Therapeutics Inc (NASDAQ: FATE) Drops -18.14 Percent In Recent Trading, What Questions Do You Have? - Stocksregister
Fate Therapeutics Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of “Hold” by Brokerages - Defense World
Fate Therapeutics Inc [FATE] Records 50-Day SMA of $1.0480 - knoxdaily.com
LPL Financial LLC Buys New Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Uncovering the Potential of Fate Therapeutics Inc (FATE) Stock - investchronicle.com
There is no way Fate Therapeutics Inc (FATE) can keep these numbers up - Sete News
Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting - The Manila Times
Fate Therapeutics to Present Clinical and Preclinical Data at ASGCT 28th Annual Meeting - Nasdaq
Was anything negative for Fate Therapeutics Inc (FATE) stock last session? - uspostnews.com
Fate Therapeutics Announces Five Presentations on - GlobeNewswire
The Attractiveness of Investing In Fate Therapeutics Inc (FATE) is Growing - knoxdaily.com
Geode Capital Management LLC Sells 31,279 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Recent uptick might appease Fate Therapeutics, Inc. (NASDAQ:FATE) institutional owners after losing 66% over the past year - Yahoo
Russell Investments Group Ltd. Increases Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
FATE CLASS ACTION: Hagens Berman Encourages Fate Therapeutics, Inc. (FATE) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Lawsuit Pending - ACCESS Newswire
FATE Shares Experience Decline in Value - knoxdaily.com
Analyzing Ratios: Fate Therapeutics Inc (FATE)’s Financial Story Unveiled - DWinneX
Ratios Revealed: Decoding Allarity Therapeutics Inc (ALLR)’s Financial Health - DWinneX
JPMorgan Chase & Co. Reduces Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics Inc [FATE] Stock trading around $1.25 per share: What’s Next? - dbtnews.com
Nothing is Better Than Fate Therapeutics Inc (FATE) stock at the moment - Sete News
Is Fate Therapeutics Inc (NASDAQ:FATE) stock a better investment at this time? - uspostnews.com
Franklin Resources Inc. Has $273,000 Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Vanguard Group Inc. Cuts Stake in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Finanzdaten der Fate Therapeutics Inc-Aktie (FATE)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):